Kornimate/medical-research-clean huggingface dataset:
pseudo-simultaneous imaging of tumor hypoxia and proliferation in hnc patients using pet/ct

Conditions: Head and Neck Cancer

Summary: 66% of hnc patients present with advanced-stage disease at initial diagnosis. the 5-year survival rates for stages iva, ivb, and ivc are 32%, 25%, and \&lt;4% respectively. accurate pre-treatment staging is vital in determining the optimum procedure for the management of hnc. early identification of non-responders may allow modification of their treatment through the introduction of more intensive therapies. identifying prognostic factors that predict patient outcome will ultimately lead to new treatment regimens. tumor hypoxia and proliferation are two key characteristics of cancer that were shown to correlate with poor response to treatment in hnc. in this proposal, the investigators assess the prognostic values of these two markers. combining information from these two biological markers shall result in prognostic information superior to those of any of the two separately. imaging those vital tumor characteristics simultaneously shall provide more coherent assessment of tumor microenvironment than does registration of corresponding images acquired in different imaging session, thus subject to uncertainties resulting from transient biologic changes and image registration process. the investigators propose to use a method that the investigators previously developed to simultaneously and non-invasively image tumor hypoxia (fmiso-pet) and proliferation (flt-pet) within a single pet/ct study. ct perfusion scan will be performed 1st, followed by pet imaging with staggered fmiso and flt injections. fmiso and flt signals will be separated retrospectively using kinetic modeling. the investigators believe imaging tumor hypoxia and cell proliferation simultaneously yield information underpinning for image-guided and radiobiological based dose painting, adaptive therapy, and patient medical management. if successful, this pilot study will constitute the basis for a nih grant proposal that aims to improve treatment outcome assessment in hnc.


Eligibility criteria:
subject inclusion criteria: * pathologic confirmation of hnc * no prior treatment for this diagnosis of hnc * patient to be treated with radio-therapy * age \>= 18 years old * karnofsky performance status \>= 70% * women of childbearing age must have a negative blood pregnancy test. exclusion criteria: * women who are pregnant or breast-feeding. * severe diabetes (fasting blood glucose \> 200- mg/dl) * adults who are unable to consent * patients who do not agree to share and store data history of lack of tolerance of the standard of care fdg-pet scan previously obtained * history of previous intolerance of either fmiso or flt.
does neuromuscular electrical stimulation improve the absolute walking distance in patients with intermittent claudication compared to best available treatment?

Conditions: Intermittent Claudication; Peripheral Vascular Diseases

Summary: intermittent claudication (ic) is caused by a blockage in the artery of the leg, causing muscle pain. although some evidence of the efficacy of neuromuscular electrical stimulation (nmes) in the management of patients with ic exists, further high quality research is required. this proposed study is vital to identify the contribution of clinical change using nmes, compared to the current gold standard recommended practice of supervised exercise therapy (set) and, actual standard of care offered in the majority of the uk and ireland, including best medical therapy (bmt). the device is expected to increase the walking distance in patients with intermittent claudication (ic), and therefore have a benefit on the same when provided in addition to supervised exercise programmes. it is also expected to cause a reduction in pain symptoms and reduced likelihood of major intervention in late stage peripheral arterial disease (pad). the principal research objective is to assess the clinical efficacy of a neuromuscular electrical stimulation (nmes) device as an adjunct to the local standard care that is available at the study randomisation sites, in order to improve walking distance in patients with intermittent claudication (ic).


Eligibility criteria:
inclusion criteria: * capacity to provide informed consent * aged 18 or above * positive edinburgh claudication questionnaire * abpi \ 30mmhg, 40 secs post 1 min treadmill at 10% gradient, 4 km/h) exclusion criteria: * severe ic requiring invasive intervention as determined by the treating clinician * critical limb ischaemia as defined by the european consensus document * co-morbid disease prohibiting walking on a treadmill or taking part in supervised exercise therapy. * popliteal entrapment syndrome * commenced vascular symptom specific medication in previous 6 months e.g. naftidrofuryl oxalate, cilostazol * pregnancy * any implanted electronic, cardiac or defibrillator device * acute deep vein thrombosis * broken or bleeding skin including leg ulceration * peripheral neuropathy * recent lower limb injury or lower back pain
a study of avastin (bevacizumab) in combination with fotemustine in patients with metastatic melanoma

Conditions: Malignant Melanoma

Summary: this study will investigate the efficacy and safety of bevacizumab + fotemustine in patients with stage iv melanoma, previously untreated with chemo- or immunotherapy for metastatic disease. patients will receive avastin (15mg/kg intravenously\[iv\]) on day 1 of every 3 week cycle, in combination with fotemustine (100mg/m² iv) on days 1, 8 and 15, followed by 4 weeks rest, followed by 100mg/m² iv every 3 weeks for 4-6 cycles. the anticipated time on study treatment is until disease progression, and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * cutaneous malignant melanoma; * advanced, inoperable stage iv melanoma; * measurable and/or evaluable sites of metastases. exclusion criteria: * prior chemotherapy and/or ifn/il2 based immunotherapy for metastatic disease; * prior malignancies within past 5 years, with the exception of cured non-melanoma skin cancer, or in situ cancer of cervix; * clinically significant cardiovascular disease; * ongoing treatment with aspirin (\>325mg/day) or other medications known to predispose to gastrointestinal ulceration.
research on the use of probiotics in the prevention and treatment of inflammatory bowel disease

Conditions: Inflammatory Bowel Disease

Summary: this project involves the use of oral lactobacillus reuteri as an adjunct therapy for 8 weeks. endoscopic observation of intestinal inflammation will be conducted at 1 month, 3 months, 6 months, and 12 months after the administration of the drug. intestinal fluid will be collected endoscopically for 16s rna analysis to assess changes in the gut microbiota. inflammatory changes in the patients will be detected through peripheral blood tests, and fecal calprotectin levels will be measured to evaluate the progression of the disease.


Eligibility criteria:
inclusion criteria: 1. be over 18 years old 2. agree to sign informed consent; have been diagnosed with ibd for at least 3 months but not more than 3 years - exclusion criteria: 1. does not meet the diagnostic criteria of cd 2. patients with other autoimmune diseases, infectious diseases and malignant tumors patients with cd during pregnancy and lactation; patients with serious diseases of the liver, kidney, heart and lung, etc 3. patients with allergic diseases such as asthma and allergic rhinitis; alcoholic patients with mental illness 4. patients with suspected cancer in their intestines 5. antibiotics, probiotics and prebiotics have been used in the past three months had intestinal surgery (except appendicitis surgery) 6. there is currently an infection 7. he has had cancer in the last 5 years -
corticosteroid therapy for persistent synovitis in acute septic arthritis on native joint

Conditions: Arthritis, Septic

Summary: acute septic arthritis is a rare but life-threatening and functionally serious disease. the improvement or disappearance of pain and functional recovery are sometimes difficult to obtain, with in some cases the persistence of synovitis due to a prolonged local inflammatory response, despite early and effective treatment. the consequences are significant for patients with often significant chronic pain, repercussions on autonomy and/or profession. an unfavorable evolution with joint destruction and need for replacement by a prosthesis is not uncommon. corticosteroid therapy is widely used in rheumatology in similar tables, for the purpose of drug synovectomy, with good results. the risk of infection remains the main contraindication to its use. there are very few studies on its use in septic arthritis, either fundamentally or in humans, for which there are no data in adults. however, these have shown results encouraging the investigators not to neglect this therapy.


Eligibility criteria:
inclusion criteria: * adult patient (≥18 years old) * having presented with septic arthritis and treated at the strasbourg university hospital between january 1, 2012 and december 31, 2021 * clinical finding of persistent synovitis, defined by the presence of pain, effusion or joint stiffness despite well-conducted treatment * having had a diagnosis of joint infection proven by a positive culture of the joint fluid to a pathogenic germ * having had treatment with local or systemic corticosteroids. exclusion criteria: * patient who has expressed his opposition to the reuse of his data for scientific research purposes. * absence of corticosteroid treatment

Keywords: arthritis, septic synovitis corticosteroid therapy inflammatory response native joint
fear of hypoglycemia in children and adolecents with type 1 diabetes

Conditions: Type 1 Diabetes Mellitus; Fear of Hypoglycemia

Summary: acute symptoms of hypoglycemia influence all aspects of every day life and reduce quality of life of children and adolescents with type 1 diabetes and their parents. encountering with hypoglycemia can result in fobic fear of low blood glucose levels in patients with type 1 diabetes and their parents.

fear of hypoglycemia is the most commonly reported problem in type 1 diabetes. by definition, hypoglycemia is a state of low blood glucose that is lower than 3,6 mmol/l. it can lead to uncomfortable counter-regulatory symptoms such as headaches, nervousness, weakness sweating, confusion, irritability, sleepiness and dizziness. in worst cases hypoglycemia can lead to loss of consciousness, seizures and death. unpredictability of episodes of hypoglycemia causes patients with diabetes and their family members to develop symptoms of anxiety and concerns related to hypoglycemia. the acute symptoms affect all fields of every day life and decrease quality of life of children and adolescents with type 1 diabetes and their parents. in some individuals and their families fear of hypoglycemia can lead to maintaining higher levels of blood glucose, excessive glucose monitoring, sleep deprivation, stress, obsessivity in self control, dependency to others etc.

Eligibility criteria:
inclusion criteria: * type 1 diabetes for more than 0.5 year * age ≥ 1 year up to 25 years (inclusive) * the subject/carer is willing to follow study specific instructions exclusion criteria: * youth with maturity-onset diabetes of the young, hybrid, other, or missing type * any significant diseases / conditions including psychiatric disorders and substance abuse that in the opinion of the investigator is likely to affect the subject's ability to complete the study * current use of the following medications: medications that are used to lower blood glucose such as pramlintide, metformin and glp-1 analogs. beta blockers, glucocorticoids and other medications, which in the judgment of the investigator would be a contraindication to participation in the study (anticoagulant therapy e.g. plavix, lmw heparin, coumadin, immunosuppressant therapy)

Keywords: type 1 diabetes mellitus fear of hypoglycemia
diode laser for harvesting gingival graft

Conditions: Gingival Recession

Summary: aims: the aim of present randomized controlled clinical study was to evaluate whether the additional use of diode laser would facilitate the donor surgery, improve the palatal wound healing and reduce post-operative morbidity after the coronally advanced flap (caf) with connective tissue (ctg) grafts. methods: fifty-two patients with isolated recessions were treated. the ctg resulted from the de-epithelialization of a free gingival graft (fgg) with blade (control group) or diode laser (dl) (test group). the dl was used to de-epithelialize the outer part of the fgg and photo-biostimulate the palatal wound area. post-operative morbidity was evaluated by using oral health related quality of life (qol), smile related qol and visual analogue scale-discomfort (vas). root coverage outcomes were also evaluated 6 months after operation.

the procedure of connective tissue harvesting from the palate is often characterized by the challenge of obtaining the largest volume of tissue possible on one side while minimizing post-operative pain and reducing the risk of complications on the other.the present clinical study evaluated whether the additional use of diode laser would facilitate the donor surgery, improve the palatal wound healing and reduce post-operative morbidity after the bilaminar periodontal plastic surgery procedure for the treatment of isolated single gingival recession defects with no loss of interdental clinical attachment. in the test sites, an aluminum, gallium, and arsenide diode laser (wavelength 810 nm and power of 1w) was applied in continuous mode. in the control group,a free (epithelialized) gingival graft was harvested by two horizontal and two vertical incisions defining the area. the post operative course of the patients were evaluated by visual analogical scale and the oral health impact profile

Eligibility criteria:
inclusion criteria: * presence of identifiable buccal cemento-enamel junction; * presence of a step ≤ 1mm at the cemento-enamel junction level * no contraindications for periodontal surgery and no periodontal surgery on the involved sites * full-mouth plaque score of \<10%; full-mouth bleeding score of \<15% * no occlusal interferences. exclusion criteria: * history of periodontitis or abscess formation * presence of systemic disease * smokers * pregnant patients.

Keywords: free gingival graft diode laser donor site mucogingival surgery
simvastatin (zocor) therapy in sickle cell disease

Conditions: Sickle Cell Disease

Summary: recent clinical and experimental data indicate that statins have effects beyond cholesterol lowering that may be beneficial in sickle cell disease by protecting the vascular endothelium. statins have been shown to attenuate endothelial dysfunction through their anti-inflammatory, anti-oxidant and anti-thrombotic properties. this phase i/ii dose-escalating trial is designed to assess the safety and potential clinical efficacy of oral simvastatin (zocor)in adolescents and adults with sickle cell disease (scd).

although statins have been used extensively for their cholesterol-lowering effects, recent clinical and experimental data indicate that statins regulate yet other processes, many of which play a major role in sickle cell disease (scd). independent of their cholesterol-lowering effects, statins have been shown to prevent damage to blood vessels in several ways, through upregulation of endothelial nitric oxide (no)and decreased inflammation. numerous studies documenting the protective effects of statins, together with data showing the therapeutic role of no in scd, provide the basis for investigating the potential clinical benefit of simvastatin in scd. data supporting the safety and tolerability of simvastatin in patients with scd are now needed. for this phase i/ii dose-escalation study of oral simvastatin in scd, we propose the following specific aims: 1. to obtain preliminary efficacy data on the effects of oral simvastatin on plasma biomarkers of endothelial injury in patients with scd, and 2. to assess the safety and tolerability of oral simvastatin in patients with scd.

Eligibility criteria:
inclusion criteria: * established diagnosis of sickle cell disease (hbss, sc or sβ-thalassemia) * age greater than or equal to thirteen years * weight greater than or equal to 35 kg exclusion criteria: * renal dysfunction (serum creatinine \> 1.5 unl) * hepatic dysfunction (alt \> 2x unl) * pretreatment total cholesterol \< 100 mg/dl or triglycerides \< 30 mg/dl * pretreatment baseline creatine kinase \>1x unl (215 u/l) * pregnancy/lactation * rbc transfusion in the last 30 days * vaso-occlusive event needing hospitalization in the past 30 days * treatment with any statin drugs within the past 30 days * treatment with drugs having known metabolic interactions with statin drugs (e.g. cytochrome p450 3a4 metabolism), including ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, azithromycin, niacin (nicotinic acid), digoxin, coumadin, sildenafil or amiodarone within the past 30 days * treatment (past or present) with amiodarone * musculoskeletal disorder associated with an elevated creatine kinase level * past or present history of substance abuse (alcohol, cocaine, amphetamines, heroin, pcp) * allergy to statins

Keywords: sickle cell disease simvastatin statin drugs nitric oxide donors vascular injury
prevention of school dropout for mexican american adolescents

Conditions: Depression; Conduct Disorder

Summary: the purpose of this study is to test the efficacy of a family-based psychosocial intervention to prevent school disengagement and reduce the incidence of depression, conduct disorders, and school dropout for mexican american adolescents.

mexican american adolescents are at an increased risk for interrelated problems of poor mental health and school dropout. unfortunately, there is a lack of interventions specifically designed to address this risk. this study will evaluate a preventive intervention for low-income mexican american adolescents. participants are randomly assigned to either a multi-component intervention called the bridges to high school program or a low dose workshop. the 11-week multi-component intervention takes place during the fall semester of seventh grade and consists of an adolescent group, a parenting group, a combined (parent-adolescent) family group, and a school liaison. this intervention focuses on adolescent coping skills, parenting practices, family cohesion, and parental support for education. the low-dose workshop consists of a 3-hour workshop in which adolescents and parents are given information and resources to facilitate school engagement. participants are assessed prior to and immediately following the intervention and again in eighth and ninth grade. academic and mental health outcomes are measured with questionnaire-based interviews given to caregivers and adolescents. teachers are asked to complete questionnaires; archival school data are also collected. diagnostic interviews are conducted at the ninth grade assessment.

Eligibility criteria:
inclusion criteria: * mexican american adolescent with at least one primary caregiver * enrolled in seventh grade in one of four inner-city schools * adolescent and participating caregivers must be able to receive intervention in the same language (english or spanish) exclusion criteria: * high risk for suicide
atrial fibrillation and the risk for neurological complications

Conditions: Atrial Fibrillation

Summary: b8: atrial fibrillation and the risk of neurological complications twenty-five thousand acute strokes are caused by atrial fibrillation every year. but even more frequent than symptomatic strokes are silent infarctions of the brain. silent strokes remain undetected in most cases, but cumulate over time and progressively impair cognition. the impact of atrial fibrillation on subacute brain infarctions is not yet known. moreover, it has not been elucidated so far how effective different therapeutic strategies in the treatment of atrial fibrillation prevent cognitive impairment. thus, this study aims at evaluating the influence of different types of atrial fibrillation on silent strokes and the related impairment in cognitive functions. other risk factors and cardiovascular diseases that are known to provoke the development of strokes will be assessed as well. so, it will be possible to isolate the contribution of atrial fibrillation to silent strokes and related cognitive impairment in segregation to other relevant factors. af patients and controls will be examined twice in two years in order to evaluate the role of atrial fibrillation and differential therapeutic interventions with regard to the progression of silent strokes and cognitive impairment in a within subject-design.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of permanent, paroxysmal or episodic atrial fibrillation in the past or at present exclusion criteria: * pacemaker * metal implants * history of acute stroke * diagnosis of vascular or degenerative dementia * history of brain tumors * history of severe brain injury * history of psychiatric disorders * pregnancy

Keywords: atrial fibrillation stroke vascular dementia mild cognitive impairment
mr-based collateral imaging to predict response to endovascular treatment of stroke (fast-coll study)

Conditions: Stroke

Summary: based on the results of recent randomized controlled trials, current international guidelines recommend the initiation of endovascular treatment within 6 hours of symptom onset for acute ischemic stroke. endovascular treatment may be beneficial in selected patients beyond 6 hour time window. in particular, treatment response to endovascular therapy may be greatly influenced by pretreatment collateral status. the aim of this study is to evaluate whether mri-based collateral imaging (the fast analysis system for collaterals, 'fast-coll') is feasible and can predict the response to endovascular treatment in a wide range of patients with acute ischemic stroke .


Eligibility criteria:
inclusion criteria: * acute ischemic stroke * age 20 years and older * disabling stroke defined as a baseline nihss \> 5 at the time of arrival * onset (last-seen-well) time to endovascular treatment time \< 12 hours * confirmed symptomatic intracranial occlusion, based on ct or mr angiography, at one or more of the following locations: carotid t/l, m1 mca, or m1-mca equivalent (2 or more m2-mcas) * signed informed consent or appropriate signed deferral of consent where approved exclusion criteria: * baseline non-contrast ct reveals a moderate/large core defined as extensive early ischemic changes of aspects 0-5 in the territory of symptomatic intracranial occlusion. * clinical history, past imaging or clinical judgment suggests that the intracranial occlusion is chronic * unable to undergo mri (contraindicated or poor cooperation) * patient has a severe or fatal comorbid illness that will prevent improvement or follow-up or that will render the procedure unlikely to benefit the patient * pregnant females as determined by positive urine hcg test or lactating females

Keywords: stroke collateral status endovascular treatment